Camille L. Bedrosian, M.D.

Board Member

Camille L. Bedrosian, M.D. has served on our board of directors since September 2020. Dr. Bedrosian currently serves as Executive Vice President and Chief Medical Officer of Ultragenyx Pharmaceutical where she provides strategic leadership to the global development and translational research programs, and oversees medical affairs, clinical development, clinical operations, regulatory affairs, patient advocacy and engagement, biometrics, and drug safety/pharmacovigilance.

Dr. Bedrosian previously was Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc., where she provided leadership for the development of drugs and drug candidates including those designed to address devastating rare diseases caused by defects in the complement system, particularly Soliris® (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Prior to her ten years at Alexion, Dr. Bedrosian spent more than five years as the Chief Medical Officer for ARIAD Pharmaceuticals, Inc., where she provided leadership for drug development, built the clinical organization, and participated in a partnership with Merck for ARIAD’s small molecule mTOR inhibitor. Before joining ARIAD, Dr. Bedrosian served from 1997 to 2002 in the Clinical Research and Development Department of Genetics Institute, Inc. (acquired by Wyeth, now part of Pfizer), where she assumed roles of increasing responsibility and became therapeutic area head for hemophilia. Earlier in her career, Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and member of the Duke Comprehensive Cancer Center, where she also completed her residency in internal medicine and fellowship in hematology and medical oncology.

Dr. Bedrosian holds an A.B. degree in Honors Chemistry from Harvard University, an M.S. degree in Biophysics from the Massachusetts Institute of Technology, and an M.D. degree from Harvard Medical School. She currently serves as a Member of the MIT Corporation Visiting Committee for the Department of Biology.